References

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Clinical Review Report: Semaglutide (Ozempic): (Novo Nordisk Canada Inc.): Indication: For the treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with metformin (second-line treatment), and in combination with metformin and sulfonylurea (third-line treatment) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jun.

Cover of Clinical Review Report: Semaglutide (Ozempic)

Clinical Review Report: Semaglutide (Ozempic): (Novo Nordisk Canada Inc.): Indication: For the treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with metformin (second-line treatment), and in combination with metformin and sulfonylurea (third-line treatment) [Internet].

Show details

Contents

< PrevNext >

References

1.: Public Health Agency of Canada. Diabetes in Canada: fact and figures from the public health perspective. 2011; https://www.canada.ca/en/public-health/services/chronic-diseases/reports-publications/diabetes/diabetes-canada-facts-figures-a-public-health-perspective.html. Accessed 2019 Mar 5.
2.: Diabetes Canada. National and provincial backgrounders (estimated prevalence and cost). Diabetes charter backgrounders 2018; https://www.diabetes.ca/diabetes-and-you/know-your-rights/support-the-diabetes-charter-for-canada/diabetes-charter-backgrounders. Accessed 2019 Mar 5.
3.: Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2018;42(Suppl 1):S1–S325. [PubMed: 29650079]
4.: Wexler DJ. Management of persistent hyperglycemia in T2DM. In: Post TW, ed. UpToDate. Watham (MA): UpToDate; 2018: www.uptodate.com. Accessed 2018 Dec 12.
5.: Lexicomp. Semaglutide: drug information. In: Post TW, ed. UpToDate. Waltham (MA): UpToDate; 2018: www.uptodate.com. Accessed 2018 Dec 12.
6.: ^PrOzempic® (semaglutide injection): 2 mg/pen (1.34 mg/mL), 4 mg/pen (1.34 mg/mL). Pre-filled pen delivering doses of 0.25 mg or 0.5 mg and pre-filled pen delivering doses of 1 mg [product monograph]. Mississauga (ON): Norvo Nordisk Canada Inc.; 2018.
7.: Clinical Study Report: NN9535-3623. SUSTAIN 1 - monotherapy. Efficacy and safety of semaglutide once-weekly versus placebo in drug-naive subjects with type 2 diabetes. Trial phase: 3a [CONFIDENTIAL internal manufacturer’s report]. Bagsvaerd (DK): Novo Nordisk; 2016.
8.: Clinical Study Report: NN9535-3627. SUSTAIN™ 5 – add on to basal insulin. Efficacy and safety of semaglutide once-weekly versus placebo as add-on to basal insulin alone or basal insulin in combination with metformin in subjects with type 2 diabetes. Trial phase: 3a. [CONFIDENTIAL internal manufacturer’s report]. Bagsvaerd (DK): Novo Nordisk; 2016.
9.: Clinical Study Report: NN9535-3744. SUSTAIN 6 – long-term outcomes. A long-term, randomised, double-blind, placebo-controlled, multinational, multi-centre trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes. Trial phase: 3a. [CONFIDENTIAL internal manufacturer’s report]. Bagsvaerd (DK): Novo Nordisk; 2016.
10.: Clinical Study Report: NN9535-3626. SUSTAIN 2 – vs. DPP-4 inhibitor. Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or TZD in subjects with type 2 diabetes. Trial phase: 3a [CONFIDENTIAL internal manufacturer’s report]. Bagsvaerd (DK): Novo Nordisk; 2016.
11.: Clinical Study Report: NN9535-3624. SUSTAIN 3. Efficacy and safety of semaglutide once-weekly versus exenatide ER 2.0 mg once-weekly as add-on to 1–2 oral antidiabetic drugs (OADs) in subjects with type 2 diabetes. Trial phase: 3a. [CONFIDENTIAL internal manufacturer’s report]. Bagsvaerd (DK): Novo Nordisk; 2016.
12.: Clinical Study Report: NN9535-3625. SUSTAIN™ 4 – vs. basal insulin. Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naive subjects with type 2 diabetes. Trial phase: 3a. [CONFIDENTIAL internal manufacturer’s report]. Bagsvaerd (DK): Novo Nordisk; 2016.
13.: Clinical Study Report: NN9535-4216. Efficacy and safety of semaglutide versus dulaglutide as addon to metformin in subjects with type 2 diabetes. Trial phase: 3a. [CONFIDENTIAL internal manufacturer’s report]. Bagsvaerd (DK): Novo Nordisk; 2016.
14.: Seino Y, Terauchi Y, Osonoi T, et al. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes Metab. 2018;20(2):378–388. [PMC free article: PMC5813234] [PubMed: 28786547]
15.: Leiter LA, Berard L, Bowering CK, et al. Type 2 diabetes mellitus management in Canada: is it improving? Can J Diabetes. 2013;37(2):82–89. [PubMed: 24070797]
16.: Clinical Study Report: NN9535-EXPLORATORY. Subgroup Analyses of SUSTAIN-2, SUSTAIN-3 and SUSTAIN-4 (draft). [CONFIDENTIAL internal manufacturer’s report]. Bagsvaerd (DNK): Novo Nordisk; 2018.
17.: International Diabetes Federation. IDF diabetes atlas - 8th edition. 2017; http://diabetesatlas.org/resources/2017-atlas.html. Accessed 2019 Mar 21.
18.: Canadian Diabetes Association. An economic tsunami: the cost of diabetes in Canada. Toronto (ON): Canadian Diabetes Association; 2009 Dec: https://www.diabetes.ca/CDA/media/documents/publications-and-newsletters/advocacy-reports/economic-tsunami-cost-of-diabetes-in-canada-english.pdf. Accessed 2019 Mar 21.
19.: World Health Organization. Global report on diabetes. Geneva (CH): World Health Organization; 2016: https://apps.who.int/iris/bitstream/handle/10665/204871/9789241565257_eng.pdf;jsessionid=8466867C7E5D5DB6BC42761C3B9CEB8F?sequence=1. Accessed 2019 Mar 21.
20.: DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of T2DM. Diabetes. 2009;58(4):773–795. [PMC free article: PMC2661582] [PubMed: 19336687]
21.: Palanisamy S, Yien ELH, Shi LW, et al. Systematic review of efficacy and safety of newer antidiabetic drugs approved from 2013 to 2017 in controlling A1C in diabetes patients. Pharmacy (Basel). 2018;6(3):57. [PMC free article: PMC6164486] [PubMed: 29954090]
22.: Sharma R, Wilkinson L, Vrazic H, et al. Comparative efficacy of once-weekly semaglutide and SGLT2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis. Curr Med Res Opin. 2018;34(9):1595–1603. [PubMed: 29764222]
23.: Aldossari KK. Cardiovascular outcomes and safety with antidiabetic drugs. Int J Health Sci (Qassim). 2018;12(5):70–83. [PMC free article: PMC6124835] [PubMed: 30202411]
24.: Del Olmo-Garcia MI, Merino-Torres JF. GLP-1 receptor agonists and cardiovascular disease in patients with type 2 diabetes. J Diabetes Res. 2018;2018:4020492. [PMC free article: PMC5902002] [PubMed: 29805980]
25.: e-CPS. Ottawa (ON): Canadian Pharmacists Association; 2018: www.e-therapeutics.ca. Accessed 2019 Feb 12.
26.: ^PrAdlyxine™ (lixisenatide injection): 0.05 mg per mL (10 μg/dose), 0.1 mg per mL (20 μg/dose), solution for injection in a pre-filled pen. Laval (QC): Sanofi-Aventis Canada Inc; 2017: https://pdf.hres.ca/dpd_pm/00039567.PDF. Accessed 2019 Feb 12.
27.: Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251–260. [PubMed: 28110911]
28.: Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103(6):2291–2301. [PMC free article: PMC5991220] [PubMed: 29688502]
29.: Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New Engl J Med. 2016;375(19):1834–1844. [PubMed: 27633186]
30.: CDR submission: Ozempic (semaglutide), 1.34 mh/mL, solution for injection in a pre-filled pen, 0.5 mg once weekly and 1.0 mg once weekly [CONFIDENTIAL manufacturer’s submission]. Mississauga (ON): Norvo Nordisk Canada Inc.; 2018.
31.: Health Canada reviewer’s report: Ozempic (semaglutide) [CONFIDENTIAL internal report]. Ottawa (ON): Therapeutics Products Directorate, Health Canada; 2018.
32.: Center for Drug Evaluation and Research. Medical review(s). Ozempic (semaglutide) subcutaneous injection. Company: Norvo Nordisk. Application No.: 209637. Approval date: 12/05/2017 (FDA approval package). Rockville (MD): U. S. Food and Drug Administration (FDA); 2017: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209637Orig1s000MedR.pdf. Accessed 2019 Jan 25.
33.: Ahren B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341–354. [PubMed: 28385659]
34.: Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41(2):258–266. [PubMed: 29246950]
35.: Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355–366. [PubMed: 28344112]
36.: Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275–286. [PubMed: 29397376]
37.: Bradley C, Plowright R, Stewart J, Valentine J, Witthaus E. The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ. Health Qual Life Outcomes. 2007;5:57. [PMC free article: PMC2170436] [PubMed: 17927832]
38.: Plowright R, Bradley C, Witthaus E. Psychometric evaluation of Diabetes Treatment Satisfaction Questionnaire (DTSQs) in eight languages. Proceedings of the British Psychological Society. 8(2):43. London (UK): Royal Holloway University of London; 2000: https://pure.royalholloway.ac.uk/portal/files/4392413/Plowright_Witthaus_and_Bradley_DTSQs_BPS_Winchester_2000_pstr.pdf. Accessed 2019 Mar 21.
39.: Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med. 2001;33(5):350–357. [PubMed: 11491194]
40.: Hill-Briggs F, Gary TL, Baptiste-Roberts K, Brancati FL. Thirty-six–item short-form outcomes following a randomized controlled trial in type 2 diabetes. Diabetes Care. 2005;28(2):443–444. [PubMed: 15677813]
41.: American Diabetes Association. Standards of medical care in diabetes - 2016. Diabetes Care. 2016;39(Suppl 1):S1–S112. [PubMed: 26696671]
42.: Center for Drug Evaluation and Research. Guidance for industry. Diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Rockville (MD): U.S. Food and Drug Administration (FDA) 2008: https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf. Accessed 2019 Mar 21.
43.: Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412. [PMC free article: PMC27454] [PubMed: 10938048]
44.: Systematic literature review and network meta-analysis to assess the relative efficacy and safety of once-weekly semaglutide compared with GLP-1 receptor agonists in patients inadequately controlled with one oral anti-diabetic drugs: technical report. CDR submission: Ozempic (semaglutide), 1.34 mh/mL, solution for injection in a pre-filled pen, 0.5 mg once weekly and 1.0 mg once weekly [CONFIDENTIAL manufacturer’s submission]. Missassauga (ON): Norvo Nordisk Canada Inc.; 2018.
45.: Systematic literature review and network meta-analysis of comparative efficacy and safety of once-weekly semaglutide relative to SGLT2 inhibitors in patients inadequately controlled with metformin monotherapy: technical report. CDR submission: Ozempic (semaglutide), 1.34 mh/mL, solution for injection in a pre-filled pen, 0.5 mg once weekly and 1.0 mg once weekly [CONFIDENTIAL manufacturer’s submission]. Missassauga (ON): Norvo Nordisk Canada Inc.; 2018.
46.: Systematic literature review and network meta-analysis to assess the relative efficacy and safety of oncw-weekly semaglutide compared with SUs in patients inadequately controlled with metformin: technical report. CDR submission: Ozempic (semaglutide), 1.34 mh/mL, solution for injection in a pre-filled pen, 0.5 mg once weekly and 1.0 mg once weekly [CONFIDENTIAL manufacturer’s submission]. Missassauga (ON): Norvo Nordisk Canada Inc.; 2018.
47.: Systematic literature review and network meta-analysis to assess the relative efficacy and safety of once-weekly semaglutide compared with GLP-1 receptor agonists in patients inadequately controlled with 1–2 oral anti-diabetic drugs: analysis at 24 ±4 weeks: technical report. CDR submission: Ozempic (semaglutide), 1.34 mh/mL, solution for injection in a pre-filled pen, 0.5 mg once weekly and 1.0 mg once weekly [CONFIDENTIAL manufacturer’s submission]. Missassauga (ON): Norvo Nordisk Canada Inc.; 2018.
48.: Systematic literature review and network meta-analysis of comparative efficacy and safety of once-weekly semaglutide relative to SGLT2 inhibitors in patients inadequately controlled with 1–2 OADs: technical report. CDR submission: Ozempic (semaglutide), 1.34 mh/mL, solution for injection in a pre-filled pen, 0.5 mg once weekly and 1.0 mg once weekly [CONFIDENTIAL manufacturer’s submission]. Missassauga (ON): Norvo Nordisk Canada Inc.; 2018.
49.: Systematic literature review and feasibility assessment to explore the relative efficacy and safety of once-weekly semaglutide compared with SGLT2is in patients with T2D inadequately controlled with 2 OADs: technical report. CDR submission: Ozempic (semaglutide), 1.34 mh/mL, solution for injection in a pre-filled pen, 0.5 mg once weekly and 1.0 mg once weekly [CONFIDENTIAL manufacturer’s submission]. Missassauga (ON): Norvo Nordisk Canada Inc; 2018.
50.: Systematic literature review and network meta-analysis of comparative efficacy and safety of once-weekly semaglutide relative to SGLT2 inhibitors in patients inadequately controlled with metformin monotherapy: appendices for technical report version 9.0. CDR submission: Ozempic (semaglutide), 1.34 mh/mL, solution for injection in a pre-filled pen, 0.5 mg once weekly and 1.0 mg once weekly [CONFIDENTIAL manufacturer’s submission]. Missassauga (ON): Novo Nordisk Canada Inc.; 2018.
51.: Sharma R, Wilkinson L, Vrazic H, et al. Comparative efficacy of once-weekly semaglutide and SGLT2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis. Curr Med Res Opin. 2018;34(9):1595–1603. [PubMed: 29764222]
52.: Zheng SL, Roddick AJ, Aghar-Jaffar R, et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase-4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA. 2018;319(15):1580–1591. [PMC free article: PMC5933330] [PubMed: 29677303]
53.: Systematic literature review and network meta-analysis of comparative efficacy and safety of once-weekly semaglutide relative to SGLT2 inhibitors in patients inadequately controlled with 1–2 OADs: appendices for technical report version 9.0. CDR submission: Ozempic (semaglutide), 1.34 mh/mL, solution for injection in a pre-filled pen, 0.5 mg once weekly and 1.0 mg once weekly [CONFIDENTIAL manufacturer’s submission]. Missassauga (ON): Norvo Nordisk Canada Inc; 2018.
54.: Witkowski M, Wilkinson L, Webb N, Weids A, Glah D, Vrazic H. A systematic literature review and network meta-analysis comparing once-weekly semaglutide with other GLP-1 receptor agonists in patients with type 2 diabetes previously receiving 1–2 oral anti-diabetic drugs. Diabetes Ther. 2018;9(3):1149–1167. [PMC free article: PMC5984927] [PubMed: 29675798]
55.: Webb N, Orme M, Witkowski M, Nakanishi R, Langer J. A network meta-analysis comparing semaglutide once-weekly with other GLP-1 receptor agonists in Japanese patients with type 2 diabetes. Diabetes Ther. 2018;9(3):973–986. [PMC free article: PMC5984907] [PubMed: 29574633]
56.: Witkowski M, Wilkinson L, Webb N, Weids A, Glah D, Vrazic H. A systematic literature review and network meta-analysis comparing once-weekly semaglutide with other GLP-1 receptor agonists in patients with type 2 diabetes previously receiving basal insulin. Diabetes Ther. 2018;9(3):1233–1251. [PMC free article: PMC5984931] [PubMed: 29713961]
57.: Fei Y, Tsoi MF, Kumana CR, Cheung TT, Cheung BMY. Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs. Int J Cardiol. 2018;254:291–296. [PubMed: 29277321]
58.: Kramer CK, Ye C, Campbell S, Retnakaran R. Comparison of new glucose-lowering drugs on risk of heart failure in type 2 diabetes: a network meta-analysis. JACC Heart Fail. 2018;6(10):823–830. [PubMed: 30196071]
59.: Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA. 2016;316(3):313–324. [PubMed: 27434443]
60.: Yoon JH, Min SH, Ahn CH, Cho YM, Hahn S. Comparison of non-insulin antidiabetic agents as an add-on drug to insulin therapy in type 2 diabetes: a network meta-analysis. Sci Rep. 2018;8(1):4095. [PMC free article: PMC5840350] [PubMed: 29511288]
61.: Zaccardi F, Dhalwani NN, Dales J, et al. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20(4):985–997. [PubMed: 29205774]
62.: Zhuang XD, He X, Yang DY, et al. Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials. Cardiovasc Diabetol. 2018;17(1):79. [PMC free article: PMC5989345] [PubMed: 29871636]
63.: Zhang YS, Weng WY, Xie BC, et al. Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials. Osteoporosis Int. 2018;29(12):2639–2644. [PubMed: 30083774]
64.: Norvo Nordisk response to January 25 2019 CDR request for additional information regarding Ozempic CDR review [CONFIDENTIAL additional manufacturer’s information]. Bagsvaerd (DNK): Norvo Nordisk; 2019.
65.: National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013: process and methods. London (UK): NICE; 2013: https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781. Accessed 2019 Mar 21. [PubMed: 27905712]
66.: Jansen JP, Trikalinos T, Cappelleri JC, et al. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health. 2014;17(2):157–173. [PubMed: 24636374]
67.: Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU technical support document 1: introduction to evidence synthesis for decision making. Sheffield (UK): Decision Support Unit, ScHARR, University of Sheffield; 2011: http://nicedsu.org.uk/wp-content/uploads/2016/03/TSD1-Introduction.final_.08.05.12.pdf. Accessed 2019 Mar 21.
68.: Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med. 2013;11(1):159. [PMC free article: PMC3707819] [PubMed: 23826681]

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK544007

Contents

< PrevNext >

PubReader
Print View
Cite this Page
Clinical Review Report: Semaglutide (Ozempic): (Novo Nordisk Canada Inc.): Indication: For the treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with metformin (second-line treatment), and in combination with metformin and sulfonylurea (third-line treatment) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jun. References.
PDF version of this title (3.6M)